1783 — Maxigen Biotech Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesAdventurousSmall CapHigh Flyer

Annual income statement for Maxigen Biotech, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	458	512	604	622	681
Cost of Revenue
Gross Profit	215	261	374	424	483
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses	397	422	476	472	501
Operating Profit	61.1	89.9	129	150	180
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	76.7	97.5	166	193	226
Provision for Income Taxes
Net Income After Taxes	63.3	87.7	139	166	190
Net Income Before Extraordinary Items
Net Income	63.3	87.7	139	166	190
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	63.3	87.7	139	166	190
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.785	1.04	1.55	1.86	2.12
Dividends per Share